MediciNova, Inc. (MNOV)
Largest Insider Buys in Sector
MNOV Stock Price History Chart
MNOV Stock Performance
About MediciNova, Inc.
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and …
Insider Activity of MediciNova, Inc.
Over the last 12 months, insiders at MediciNova, Inc. have bought $0 and sold $0 worth of MediciNova, Inc. stock.
On average, over the past 5 years, insiders at MediciNova, Inc. have bought $69,240 and sold $17,077 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,000 shares for transaction amount of $7,240 was made by Matsuda Kazuko (Chief Medical Officer) on 2020‑03‑13.
List of Insider Buy and Sell Transactions, MediciNova, Inc.
| 2022-11-28 | Sale | director | 6,754 0.0116% | $2.25 | $15,197 | -16.35% | ||
| 2022-11-22 | Sale | director | 218 0.0004% | $2.13 | $464 | +5.19% | ||
| 2022-11-21 | Sale | director | 5,365 0.0112% | $2.18 | $11,696 | +4.69% | ||
| 2022-11-17 | Sale | director | 309 0.0006% | $2.18 | $674 | +2.29% | ||
| 2021-03-11 | Sale | director | 2,354 0.0052% | $7.40 | $17,420 | -47.29% | ||
| 2020-09-15 | Sale | director | 1,000 0.0022% | $5.78 | $5,780 | -11.94% | ||
| 2020-03-13 | Chief Medical Officer | 2,000 0.0041% | $3.62 | $7,240 | +38.71% | |||
| 2020-03-12 | President and CEO | 20,000 0.0451% | $3.10 | $62,000 | +78.59% | |||
| 2017-08-21 | director | 5,000 0.0148% | $5.17 | $25,850 | +71.53% | |||
| 2017-05-15 | director | 2,000 0.0056% | $5.60 | $11,200 | +15.24% | |||
| 2017-05-12 | director | 48,000 0.1421% | $5.62 | $269,760 | +20.44% | |||
| 2016-09-15 | director | 23,600 0.0662% | $6.44 | $151,984 | -10.96% | |||
| 2016-09-09 | director | 20,000 0.06% | $6.67 | $133,400 | -7.75% | |||
| 2016-07-05 | Sale | Vice President | 6,600 0.0155% | $6.40 | $42,240 | -22.50% | ||
| 2014-12-10 | director | 24,000 0.1054% | $3.54 | $84,960 | +4.48% | |||
| 2014-11-26 | director | 20,000 0.0812% | $3.07 | $61,400 | +11.78% | |||
| 2014-11-20 | director | 26,000 0.1112% | $3.19 | $82,940 | +13.23% | |||
| 2014-11-19 | director | 10,000 0.04% | $2.86 | $28,600 | +18.18% | |||
| 2014-09-11 | director | 20,000 0.084% | $2.95 | $59,000 | +22.68% | |||
| 2014-09-03 | director | 30,000 0.132% | $2.66 | $79,698 | +42.80% |
Insider Historical Profitability
| IWAKI YUICHI | President and CEO | 780683 1.5917% | $2.11 | 15 | 0 | +31.46% |
| Izumi Tatsuo | director | 600000 1.2233% | $2.11 | 5 | 1 | <0.0001% |
| Matsuda Kazuko | Chief Medical Officer | 111746 0.2278% | $2.11 | 1 | 0 | +38.71% |
| Kalafer Michael E | Chief Medical Officer | 31744 0.0647% | $2.11 | 1 | 0 | |
| Kobayashi Yutaka | director | 25000 0.051% | $2.11 | 9 | 0 | +12.44% |
Institutional Investor Ownership
| Essex Woodlands Management Inc | $1.6M | 2.26 | 1.11M | 0% | +$0 | 0.47 | |
| BlackRock | $1.01M | 1.42 | 695,420 | -0.6% | -$6,121.91 | <0.0001 | |
| The Vanguard Group | $903,833.00 | 1.27 | 623,333 | 0% | +$0 | <0.0001 | |
| Citigroup | $649,538.00 | 0.91 | 447,957 | 0% | +$0 | <0.0001 | |
| Geode Capital Management | $635,080.00 | 0.89 | 437,860 | +0.49% | +$3,085.04 | <0.0001 |